Aug 2026· Cellular Signalling· pp.
112844
· 0 citations· 32 references
Medicine
TL;DR
The TGF-β1/TWIST2/TPI1 signaling axis is defined as an important regulator of pathogenic fibroblast behavior and pro-fibrotic responses through transcriptional control of TPI1, highlighting its potential as a therapeutic target for IPF.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease characterized by aberrant profibrotic signaling and excessive extracellular matrix deposition, accompanied by fibroblast-to-myofibroblast transition. Despite extensive investigation, the molecular mechanisms underlying IPF pathogenesis remain incompletely understood. Here, we investigated the role of triosephosphate isomerase 1 (TPI1) in IPF progression and its regulation by transforming growth factor-β (TGF-β) signaling. Loss-of-function analyses identified TPI1 as a downstream effector of TGF-β1, as its knockdown markedly suppressed fibrotic marker expression, fibroblast proliferation, and migration. Mechanistically, TWIST2 was shown to function as a direct transcriptional regulator of TPI1, binding to its promoter and promoting transcriptional activation. Rescue experiments further confirmed that the TWIST2-TPI1 axis is central to the progression of pulmonary fibrosis. Notably, knockdown of either TPI1 or TWIST2 effectively attenuated TGF-β1-induced fibrotic phenotypes. Collectively, these findings define the TGF-β1/TWIST2/TPI1 signaling axis as an important regulator of pathogenic fibroblast behavior and pro-fibrotic responses through transcriptional control of TPI1, highlighting its potential as a therapeutic target for IPF.
It is concluded that mTORC1 plays a key role in shaping the transcriptional identity of these fibroblasts, with implications for therapeutic inhibition of mTORC1 in fibrosis and cancer.
J. A. Wilson, Rachel Walters, G. Contento et al.· Science Advances· 1 citation
Overall, CDC20 exacerbated pulmonary fibrosis by inhibiting fibroblast autophagy via blocking the mTOR signaling pathway, which suggested that targeting CDC20 might hold putative therapeutic effect in IPF.
Ya-Tao Guo, Meng-Chan Zhu, Ru-Yi Li et al.· Cellular Signalling· 0 citations
These findings identify SMAD4 K45 acetylation as a critical molecular switch in fibrogenesis and position CUDC-907 as a promising epigenetic strategy for the treatment of fibrotic lung diseases.
Abstract Objective Liver fibrosis is characterised by excessive accumulation of extracellular matrix and can ultimately progress to cirrhosis and malignant transformation. Activation of hepatic stellate cells (HSCs), largely driven by transforming growth factor-beta (TGF-β) signalling, is a central event in fibrogenesi...
Tong Liu, Meng-Ru Wang, G. Zheng et al.· BMJ Open Gastroenterology· 0 citations
It is suggested that MAGI2 acts as a negative regulator of myofibroblast differentiation by stabilizing PTEN, whereas PREX2 is aberrantly expressed in the fibrotic milieu, negatively modulating MAGI2, thereby accelerating pulmonary fibrosis.
Yozo Sato, K. Kamio, Yasuhiro Terasaki et al.· American Journal of Physiolo...· 0 citations
Abstract Background Keloids, which are characterized by excessive collagen deposition and fibroblast hyperactivation, present significant therapeutic challenges because of their high recurrence rates and incompletely understood pathogenesis. The transforming growth factor-β (TGF-β) pathway is a central driver, but its...